The Chemotherapy Induced Neutropenia market size is witnessing a substantial increase owing to the increasing population of cancer patients, increasing uptake of chemotherapy, and upcoming pipeline therapies in the 7MM.
LAS VEGAS, July 1, 2021 /PRNewswire/ -- DelveInsight's Chemotherapy Induced Neutropenia (CIN) Marketreport offers comprehensive coverage of the current treatment practices, pipeline drugs, Chemotherapy Induced Neutropenia market share of the individual therapies, current and forecasted CIN market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).
The total estimated number of cancer patients on chemotherapy was 1,790,618 in 2020 in the 7MM.
Surprisingly, Japan accounts for the largest Chemotherapy Induced Neutropenia prevalence after the US in the 7MM. The driving factor for the highest cases in Japan is due to the high number of colorectal cancer cases.
The Chemotherapy Induced Neutropenia epidemiological analysis for the US demonstrated Breast cancer accounting for the maximum number of Chemotherapy Induced Neutropenia prevalence out of various forms of cancers such as Lung cancer, Ovarian cancer, AML, Lymphoma, and others, with CIN cases in AML being the lowest.
Current treatments in the Chemotherapy Induced Neutropenia therapy market are limited to two approved biologics such as Neupogen (filgrastim) and Neulasta (pegfilgrastim) and their biosimilars.
The Chemotherapy Induced Neutropenia market size of Neupogen and Neulasta was USD 216 million and USD 2,450 million in 2020 in the 7MM.
The Chemotherapy Induced Neutropenia market share of biologics is expected to decline owing to the entry of biosimilars as well as novel therapies.
Major key players leading the Chemotherapy Induced Neutropenia market size growth ahead include Spectrum Pharmaceuticals, Evive Biotech, Cellerant Therapeutics, BeyondSpring Pharmaceuticals, and others.
Emerging therapies such as Rolontis (eflapegrastim injection), EC-18, ALRN-6924, Romyelocel-L/CLT-008, Myelo001, Plinabulin, F-627 (Ryzneuta), and others in the CIN market explore novel mechanisms of action, which is expected to provide them a leeway to establish a hold in the Chemotherapy Induced Neutropenia market once approved.
Pipeline therapies such as Rolontis (Spectrum Pharmaceuticals), Plinabulin (BeyondSpring Pharmaceuticals), and F-627 (Evive Biotech) are anticipated to enter the CIN market in the forecast period.
Recently in February 2021, the USFDA approved Cosela (G1 Therapeutics) to decrease the incidence of Chemotherapy Induced Myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for ES-SCLC.
Chemotherapy Induced Neutropenia (CIN) is the primary dose-limiting toxicity in patients undergoing cancer treatments with chemotherapy. It can lead to febrile neutropenia (FN), and it is associated with increased morbidity and early mortality, increased medical costs, and disruptions in potentially curative treatments. Some of the risk factors for CIN are older age, female gender, poor performance status, albumin level <3.5 g/dL, bone marrow involvement, high LDH, low lymphocyte counts, high-risk chemotherapy regimen, and others.
The risk of infection in CIN patients ranges between 10% and 50% for patients with solid tumors and more than 80% for hematological malignancies. As per DelveInsight's Chemotherapy Induced Neutropenia epidemiology analysis, the US accounted for the majority of the cancer patients on chemotherapies with 70% of the total patients on chemotherapy on intermediate-high risk for CIN.
The only strategy to manage Chemotherapy Induced Neutropenia is to prevent it. Neutropenia can be avoided or ameliorated by giving less chemotherapy or by stimulating marrow recovery immediately after chemotherapy, using the colony-stimulating factor (CSFs).
The treatment that follows in the case of Neutropenia is associated with fever includes Broad-spectrum antibiotics. Broad-spectrum antibiotics such as MEP are used as first-line antibiotics in all cases. (Hashiguchi et al. (2015)). In addition to these, Myeloid growth factors (MGFs), CSFs such as G-CSF and GM-CSF are an integral part of the prevention of potentially life-threatening Febrile Neutropenia, however, only G-CSF has US FDA approval for use in CIN. Available biosimilars in the US Chemotherapy Induced Neutropenia therapy market of Neulasta include Fulphila, Udenyca, Ziextenzo, and Nyvepria and of Neupogen are Granix, Zarxio/Zarzio, and Nivestym.
Despite the fact that CSFs have managed to improve patient quality to a profound extent, the drug class needs to be studied further for a proper understanding of its safety and efficacy profile. Further, the issue of compromised patient compliance with the available pharmacological therapies adds to the intricacy of the lot.
The Chemotherapy Induced Neutropenia therapy market is observing several therapies emerging in the foreseeable future based on novel mechanisms. This also implies that the CIN market is expected to heat up with competition as the emerging therapies will vie to compete for market share, which at the moment is occupied by biologics and their biosimilars as well. However, the Chemotherapy Induced Neutropenia pipeline possesses potential drugs for intermediate-high risk patients, which can lend pipeline therapies a leg-up.
Interested in knowing which pharma company is expected to establish a major hold in the market? Drop your query at email@example.com
Factors Impacting the Chemotherapy Induced Neutropenia Market Dynamics
A lack of understanding of the pathophysiology of the complication and unclear diagnosis modalities delays the treatment. Besides diagnosis, the present CIN market sees a limited number of therapies that explore novel mechanisms of action with poor patient compliance. The high cost of the therapies also puts a question mark on the cost-effectiveness of the therapies.
However, the gaps in the present treatment market offer pharma players tremendous opportunities to nab. Undoubtedly, the Chemotherapy Induced Neutropenia pipeline is robust and rich, exploring novel MoAs and aiming to address intermediate-high-risk patients. Pipeline therapies with better safety for long-term use and low treatment duration that are also economical and offer better patient adherence are expected to spark a great deal of change in the CIN therapy market.
Along with efficient pipeline therapies, the growing cancer patient pool will have a direct relation with the increasing CIN patient pool, which further would increase the demand for better therapies, thereby pushing the Chemotherapy Induced Neutropenia market size growth.
Know more about therapies, and pharma companies such as PledOx/Solasia, WEX Pharmaceuticals, Asahi Kasei, MediciNova, Achelios Therapeutics, Esteve, ChromaDex, Apollo endosurgery (Lpath), Hoffmann-La Roche, Midatech/DARA, Lee's Pharmaceutical Limited, Novartis, Relief Therapeutics and others working involved in the market.
Know more about therapies, and pharma companies such as Spectrum Pharmaceuticals, Mylan Pharmaceuticals, Coherus Biosciences, Enzychem, Cinfa Biotech S.L., Sandoz Pharmaceuticals, Myelo Therapeutics, Aileron Therapeutics, Cinfa Biotech S.L., Sandoz Pharmaceuticals, and others working involved in the market.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.